Cargando…

Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes

BACKGROUND: The majority of patients diagnosed with advanced epithelial ovarian carcinoma (EOC) relapse with resistant disease, and there are no biomarkers that possess clinical utility to identify or monitor these patients. This study aimed to identify secreted proteins (‘secretome') collected...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teng, P-N, Wang, G, Hood, B L, Conrads, K A, Hamilton, C A, Maxwell, G L, Darcy, K M, Conrads, T P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3887292/ https://www.ncbi.nlm.nih.gov/pubmed/24178762 http://dx.doi.org/10.1038/bjc.2013.687

Ejemplares similares

The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro
por: O'Brien, P M, et al.
Publicado: (2008)

Role of lymphangiogenesis in epithelial ovarian cancer
por: Sundar, S S, et al.
Publicado: (2006)

Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes
por: Shapira, I, et al.
Publicado: (2014)

The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer
por: de Graeff, P, et al.
Publicado: (2008)

Enhanced expression of peroxisome proliferator-activated receptor gamma in epithelial ovarian carcinoma
por: Zhang, G Y, et al.
Publicado: (2005)

BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers
por: Lee, Y-K, et al.
Publicado: (2009)

ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival
por: Brüning-Richardson, A, et al.
Publicado: (2011)

A distinct molecular profile associated with mucinous epithelial ovarian cancer
por: Heinzelmann-Schwarz, V A, et al.
Publicado: (2006)

Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques
por: Ring, A E, et al.
Publicado: (2005)

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models
por: Oliva, P, et al.
Publicado: (2012)

Creation of immortalised epithelial cells from ovarian endometrioma
por: Bono, Y, et al.
Publicado: (2012)

Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis
por: de Graeff, P, et al.
Publicado: (2009)

Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells
por: McPherson, R A C, et al.
Publicado: (2009)

Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients
por: Hosono, S, et al.
Publicado: (2007)

C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma
por: Mahner, S, et al.
Publicado: (2008)

Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer
por: Le Page, C, et al.
Publicado: (2006)

Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications
por: Gakiopoulou, H, et al.
Publicado: (2007)

The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer
por: Trinh, X B, et al.
Publicado: (2009)

High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma
por: Cheng, W-F, et al.
Publicado: (2009)

TNFAIP8 as a predictor of metastasis and a novel prognostic biomarker in patients with epithelial ovarian cancer
por: Liu, T, et al.
Publicado: (2013)

Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells
por: Johansson, D, et al.
Publicado: (2010)

Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial–mesenchymal transition in ovarian carcinomas
por: Colomiere, M, et al.
Publicado: (2009)

Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo
por: Gassler, N, et al.
Publicado: (2005)

Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer
por: Schaefer, C, et al.
Publicado: (2005)

NUAK1 (ARK5) Is Associated with Poor Prognosis in Ovarian Cancer
por: Phippen, Neil T., et al.
Publicado: (2016)

The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue
por: Oladipo, O, et al.
Publicado: (2011)

Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer
por: Peeters, D J E, et al.
Publicado: (2011)

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes
por: Peeters, D J E, et al.
Publicado: (2014)

Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies
por: de Graeff, P, et al.
Publicado: (2006)

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts
por: Huhtinen, K, et al.
Publicado: (2009)

The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer
por: Popple, A, et al.
Publicado: (2012)

Establishment of an immortalised human ovarian surface epithelial cell line without chromosomal instability
por: Maeda, T, et al.
Publicado: (2005)

E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer
por: Trillsch, Fabian, et al.
Publicado: (2016)

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin
por: Tiseo, M, et al.
Publicado: (2013)

Circulating microRNAs as prognostic therapy biomarkers in head and neck cancer patients
por: Summerer, I, et al.
Publicado: (2015)

Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype
por: Ameri, K, et al.
Publicado: (2010)

Circulating galectins -2, -4 and -8 in cancer patients make important contributions to the increased circulation of several cytokines and chemokines that promote angiogenesis and metastasis
por: Chen, C, et al.
Publicado: (2014)

Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma
por: Bhatt, R S, et al.
Publicado: (2011)

MDM2 promotes epithelial–mesenchymal transition and metastasis of ovarian cancer SKOV3 cells
por: Chen, Ying, et al.
Publicado: (2017)

Nicotine increases the resistance of lung cancer cells to cisplatin through enhancing Bcl-2 stability
por: Nishioka, T, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_u1j8t4ohuqgb8btf1qinjei723